China Pharma Receives $25M R&D Milestone Payment from AstraZeneca on July 10

According to China Pharma Holdings (CNSP) announcement, the company received a $25 million R&D milestone payment from AstraZeneca on July 10, 2026. This follows an initial payment received on May 29, 2026. The partnership focuses on developing novel long-acting peptide drugs leveraging CNSP's extended-release delivery platform and peptide AI discovery technology.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments